在代谢性疾病中,progranulin的分子机制和向治疗
Xiaxia Wang1, Yonglin Liang1, Fan Yang2
1School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Frontiers in endocrinology
|April 28, 2025
概括
益格拉努林 (PGRN) 是一种有前途的治疗点,用于治疗骨关节炎和糖尿病等代谢障碍. 对其复杂作用的进一步研究可能会导致对软骨退化和骨重塑问题的新治疗方法.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 代谢性疾病研究研究
背景情况:
- 进激素 (PGRN) 是一种具有抗炎,组织修复和代谢调节功能的糖蛋白.
- 由于复杂的致病机制,诸如骨关节炎和糖尿病等代谢障碍缺乏有效的治疗方法.
- 由于组织特异性和上下文依赖的作用,PGRN在这些疾病中的作用尚不清楚.
研究的目的:
- 审查PGRN的结构,功能和参与神经,免疫-炎症和代谢疾病.
- 专注于PGRN在代谢性疾病中的分子机制,包括软骨退化和骨重塑.
- 巩固针对PGRN及其衍生物Atsttrin在代谢性骨疾病方面的进展.
主要方法:
- 关于Progranulin (PGRN) 的研究文献综述.
- 在各种疾病模型中分析PGRN的分子机制.
- 巩固关于PGRN向策略和Atsttrin应用的研究.
主要成果:
- PGRN表达与流行代谢性疾病的发病和进展有关.
- PGRN具有双重作用 (抗炎与促炎) 和组织特异性作用.
- 阿斯特林是一种工程PGRN衍生物,在代谢性骨疾病中显示出潜力.
结论:
- PGRN是一种潜在的多效应治疗策略,用于代谢障碍.
- 了解PGRN的确切作用对于开发有效治疗非常重要.
- 本综述为推进基于PGRN的治疗策略提供了一个框架.
更多相关视频
07:58Establishment of a Surgically-induced Model in Mice to Investigate the Protective Role of Progranulin in Osteoarthritis
Published on: February 25, 2014
27.4K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.5K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
Regulated Protein Degradation
2.4K
2.4K
Protein Networks
3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
